Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fMRI analysis of the visual cortex in neovascular age-related macular degeneration
2013-004769-15Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Retinotopic maps of nAMD patients and healthy controls. Started Nov 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-004769-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004769-15.